Literature DB >> 21821525

Remote ischemic preconditioning: current knowledge, unresolved questions, and future priorities.

Karin Przyklenk1, Peter Whittaker.   

Abstract

Remote ischemic preconditioning (RIPC) is the phenomenon whereby brief episodes of ischemia-reperfusion applied in distant tissues or organs render the myocardium resistant to a subsequent sustained episode of ischemia. Reduction of infarct size with RIPC has been documented in response to (i) brief antecedent ischemia in a remote coronary vascular bed (intra-cardiac protection); (ii) collection and transfer of coronary effluent from perconditioning "donor" hearts to naive "receptor" hearts (inter-cardiac protection); (iii) brief ischemia applied in skeletal muscle, mesentery, and other organs (interorgan protection); and (iv) remote nociception ("remote PC of trauma"). Moreover, the paradigm has expanded to encompass temporal modifications in the application of the remote stimulus (remote perconditioning and remote postconditioning). Progress has also been made in translating the concept of RIPC to patients undergoing planned ischemic events: evidence for attenuation of cardiac enzyme release with RIPC has been reported after elective abdominal aortic aneurysm repair, angioplasty, and coronary artery bypass graft surgery. However, despite these advances in characterization and clinical application, the mechanisms of RIPC--most notably, the means by which the protective stimulus is communicated to the heart--remain poorly defined and, in all likelihood, are model dependent.

Entities:  

Mesh:

Year:  2011        PMID: 21821525     DOI: 10.1177/1074248411409040

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  38 in total

1.  Factors mediating remote preconditioning of trauma in the rat heart: central role of the cytochrome p450 epoxygenase pathway in mediating infarct size reduction.

Authors:  Garrett J Gross; Anna Hsu; Eric R Gross; John R Falck; Kasem Nithipatikom
Journal:  J Cardiovasc Pharmacol Ther       Date:  2012-03-09       Impact factor: 2.457

2.  Endogenous cardioprotection by ischaemic postconditioning and remote conditioning.

Authors:  Weiwei Shi; Jakob Vinten-Johansen
Journal:  Cardiovasc Res       Date:  2012-02-09       Impact factor: 10.787

Review 3.  Remote ischemic preconditioning for kidney protection: GSK3β-centric insights into the mechanism of action.

Authors:  Zhangsuo Liu; Rujun Gong
Journal:  Am J Kidney Dis       Date:  2015-08-10       Impact factor: 8.860

4.  Involvement of glycogen synthase kinase-3β in liver ischemic conditioning induced cardioprotection against myocardial ischemia and reperfusion injury in rats.

Authors:  Shuai Yang; Geoffrey W Abbott; Wei Dong Gao; Jin Liu; Chaozhi Luo; Zhaoyang Hu
Journal:  J Appl Physiol (1985)       Date:  2017-02-02

Review 5.  Ischaemic conditioning: pitfalls on the path to clinical translation.

Authors:  Karin Przyklenk
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

6.  Remote ischemic preconditioning to prevent cardiac surgery-related acute kidney injury: how far away from a breakthrough?

Authors:  Patrick M Honore; Rita Jacobs; Herbert D Spapen
Journal:  Ann Transl Med       Date:  2016-08

Review 7.  Remote ischemic preconditioning for myocardial protection: update on mechanisms and clinical relevance.

Authors:  Rabia Gill; Robin Kuriakose; Zachary M Gertz; Fadi N Salloum; Lei Xi; Rakesh C Kukreja
Journal:  Mol Cell Biochem       Date:  2015-01-01       Impact factor: 3.396

8.  Platelet-derived microvesicles are involved in cardio-protective effects of remote preconditioning.

Authors:  Fang Ma; Hengchao Liu; Yong Shen; Yingjie Zhang; Shaojun Pan
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

9.  microRNA-144: the 'what' and 'how' of remote ischemic conditioning?

Authors:  Karin Przyklenk
Journal:  Basic Res Cardiol       Date:  2014-07-31       Impact factor: 17.165

10.  Remote ischemic perconditioning is effective alone and in combination with intravenous tissue-type plasminogen activator in murine model of embolic stroke.

Authors:  Md Nasrul Hoda; Shahneela Siddiqui; Samuel Herberg; Sudharsan Periyasamy-Thandavan; Kanchan Bhatia; Sherif S Hafez; Maribeth H Johnson; William D Hill; Adviye Ergul; Susan C Fagan; David C Hess
Journal:  Stroke       Date:  2012-08-21       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.